Episode

Peptides: who's using them and what's in them?

Podcast
Health Report
Published
May 22, 2026
Duration seconds
2692
Processing state
not_requested
Canonical source
https://www.abc.net.au/listen/programs/healthreport/peptides-risks-uses-safety-in-australia/106643154
Audio
https://mediacore-live-production.akamaized.net/audio/02/kq/Z/lv.mp3
JSON
/v1/public/podcasts/health-report-318292/episodes/peptides-who-s-using-them-and-what-s-in-them
Markdown
/podcast/health-report-318292/peptides-who-s-using-them-and-what-s-in-them.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/health-report-318292/episodes/peptides-who-s-using-them-and-what-s-in-them/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/health-report-318292/peptides-who-s-using-them-and-what-s-in-them.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

The popularity of peptides appears to be growing in Australia - what do we know about who is using them, what's in them and the risks? A large study of Australians with Parkinson's disease finds links to certain pesticides and high-risk occupations. For people with heart failure, there's a procedure that you can avoid with no ill-effect. And an outbreak of diptheria across multiple states in Australia - how did this happen? References Obesity and cardiovascular disease: A clinical consensus statement from the National Heart Foundation of Australia Impact and Effectiveness of Australia's 2025 Hybrid RSV Immunisation Program: Results from the PAEDS-FluCAN Network Diphtheria outbreak could be 'contained within months' but response criticised as too slow Responding to injectable synthetic peptide use among young people: priorities for clinicians and public health Insights from a cross-sectional population-based study of 10,929 Australians living with Parkinson's disease: risk factors, comorbidities, and sex differences Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial